Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus KYGEVVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus KYGEVVI.
IMPOYZ vs KYGEVVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
KygeVVI is a fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF), binding to VEGF-A and VEGF-B and placental growth factor (PlGF), thereby inhibiting angiogenesis and tumor growth.
100 mg orally twice daily
5 mg/kg intravenously once every 14 days for 6 cycles, then 5 mg/kg once every 28 days as maintenance therapy.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 72 hours (range 60-90 hours) in patients with normal hepatic function, supporting weekly dosing intervals.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily hepatic metabolism via CYP3A4, with <1% excreted unchanged in urine. Biliary/fecal elimination accounts for ~90% of metabolites.
Category C
Category C
Unknown
Unknown